Navigation Links
UCB Announces FDA Filing for lacosamide in the Treatment of Diabetic Neuropathic Pain
Date:11/29/2007

U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for the use of lacosamide in the treatment of adults

with diabetic neuropathic pain.

ATLANTA, Nov. 29 /PRNewswire/ -- UCB announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for the use of lacosamide in the treatment of diabetic neuropathic pain. The application relates to the tablet formulation of lacosamide, whose proposed trade name is Vimpat(TM).

"The fact that a high proportion of patients with diabetic neuropathic pain do not achieve satisfactory pain relief with current management options is a powerful stimulus to research and develop new therapies," said Iris Loew- Friedrich, MD, PhD, Global Head of Development, UCB. "The FDA acceptance for review means that a full assessment will be carried out on lacosamide's potential to provide sustained pain relief in patients with moderate to severe diabetic neuropathic pain."

In placebo-controlled clinical trials of over 800 people with diabetic neuropathic pain, significant and sustained reductions in pain scores were seen versus placebo. The pain relief achieved with lacosamide was associated with reduced interference with sleep and general activities. The most common adverse events of lacosamide (greater than or equal to 10%) reported in these trials included dizziness, nausea, tremor and headache.

A similar filing made to the European Medicines Agency (EMEA) earlier this year for the use of lacosamide in the treatment of diabetic neuropathic pain, was also accepted and is currently under review.

About Diabetic Neuropathic Pain: Diabetic Neuropathic Pain is a painful and potentially debilitating condition, resulting from damage or dysfunction to the peripheral nervous system as a result of diabetes or impaired glucose tolerance. The condition is often characterized by a stabbing or burning sensation in the legs, feet, and/or hands. With the overall prevalence of diabetes in the U.S. estimated at 20.8 million people, it is thought that as many as 7.7 million have some degree of diabetic neuropathic pain.

About Lacosamide: Lacosamide has a novel and dual mode of action. It selectively enhances slow inactivation of sodium channels and interacts with the neuroplasticity-relevant target-collapsin-response mediator protein-2 (CRMP-2).

About UCB

UCB, Brussels, Belgium (http://www.ucb-group.com) is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. UCB focuses on securing a leading position in severe disease categories. Employing more than 10,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. UCB S.A. is listed on the Euronext Brussels Exchange and, through its affiliate, owns approx. 89% of the shares of SCHWARZ PHARMA AG. SCHWARZ PHARMA (Monheim, Germany) is a member of the UCB Group.

Forward looking statement

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.


'/>"/>
SOURCE UCB, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... As part ... two webinars in February 2016. Each webinar features a dynamic expert and thoughtful ... benefit their athletes, patients and facilities. Both events are free to attend, but ...
(Date:2/10/2016)... ... February 10, 2016 , ... Emergency rooms provide emergency care to ... this can leave patients with dental emergencies at risk of losing a tooth or ... dental care. , Common dental emergencies include:, , Avulsed ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... bring together more than 200 of the country’s top healthcare executives to share ... “The true benefit of the Forum is the provider-centric perspective, experience, expertise and ...
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: The ... and inspirational speaker Jan Fox will serve as keynote speaker at the organization’s ... participants with tools to more effectively communicate with their own organizational staff and ...
(Date:2/10/2016)... ... 10, 2016 , ... Everseat has joined the award-winning Allscripts ... physicians. The integration will enable Allscripts users to post open appointments to the ... app. , The partnership gives Everseat substantial added power to help Allscripts meet ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... Feb. 9, 2016  Until recently, the options for ... liposuction. Thankfully, the FDA approved the non-invasive Coolsculpting treatment, ... Coolsculpting was originally approved in 2010 for the abdomen ... now the chin. With this add-on approval, the experts ... a smaller applicator, the CoolMini, to address smaller areas ...
(Date:2/10/2016)... India , February 10, 2016 ... The "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic ... Trends, Technologies, Participants, and Environment" research report indicates ... worth over $149 billion by 2020 growing at ... up of companion diagnostics and targeted therapeutics and ...
(Date:2/9/2016)... , Feb. 9, 2016 /PRNewswire/ - Nevro Corp. ... that is providing innovative evidence-based solutions for the treatment ... financial results for the fourth quarter and full year ... 2016. Company management will host a conference call beginning ... on Monday, February 29, 2016. www.nevro.com . ...
Breaking Medicine Technology: